Skip to content
10-K

Annual Report

INHIBRX BIOSCIENCES, INC. INBX

0002007919-25-000019

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 28, 2025 14.48M sh
Shares Diluted FY 2024 · Dec 31, 2023 11.78M sh
Capex FY 2024 · Dec 31, 2023 $4.59M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$193.31M
Long Term Debt FY 2024 · Dec 31, 2023 $206.97M
Cash And Equivalents FY 2024 · Dec 31, 2023 $277.92M
Current Liabilities FY 2024 · Dec 31, 2023 $56.31M
Total Liabilities FY 2024 · Dec 31, 2023 $264.39M
Current Assets FY 2024 · Dec 31, 2023 $295.36M
Total Assets FY 2024 · Dec 31, 2023 $307.89M
Eps Diluted FY 2024 · Dec 31, 2023 −$20.48
Eps Basic FY 2024 · Dec 31, 2023 −$20.48
Sga Expense FY 2024 · Dec 31, 2023 $29.38M
Rd Expense FY 2024 · Dec 31, 2023 $191.64M
Net Income FY 2024 · Dec 31, 2023 −$241.36M
Operating Income FY 2024 · Dec 31, 2023 −$219.22M
Revenue FY 2024 · Dec 31, 2023 $1.8M
Stockholders Equity FY 2024 · Dec 31, 2022 $58.06M